


REACTION BIOLOGY

Integrated Drug Discovery:

THE REACTION ONCOLOGY PLATFORM

- Comprehensive
- Collaborative
- Consistent
- Cross-Disciplinary

Working together under one contract
for seamless transitions.



Leverage the scientific expertise
of our chemists, biologists,
and pharmacologists
for the successful
discovery of new
cancer drugs.

Let's Discover Together.



We are dedicated to find new cures against cancer. And so are our clients...

We have founded two companies for drug discovery in extremely challenging sectors - epitranscriptomics and phosphatase biology. For both projects we have partnered with Reaction Biology. Tackling drug discovery projects that are based on novel and rapidly evolving science requires a CRO with profound know-how and a specific mindset - a focus on customers, the ability to think out of the box, and the capability to provide highly customized screening and assay solutions. We found all that in our relationship with Reaction Biology.

Dr Birgit Zech

CEO, AnavoTherapeutics BV



Reaction Biology has provided their service for numerous projects with us, especially on multiple kinase assays which have guided our way through drug development. I was very impressed not only by their level of expertise and professionalism but also by their enthusiasm and drive to deliver without delay. The insightful advice they provide has been instrumental to our successes, and the reproducibility, quality, and reporting of the results have been outstanding throughout the many years we have been working together.

Dr Laurent Meijer

Chair & Chief Scientific Officer at
Perha Pharmaceuticals & ManRos Therapeutics



from Sea to Pharmacy



Quality data, quality support.

The Reaction Oncology Platform is Reaction Biology's answer to the growing demand of integrated drug discovery needs. Our broad portfolio and global network of partners enable us to provide end-to-end service for the discovery of new cancer therapeutics by holding true to our values: quality data, quality support.

Our expertise spans all phases of preclinical drug discovery, including target validation, hit identification, hit-to-lead, and lead optimization with integrating medicinal chemistry and ADME via long-term partners.

2001



Founded in
Malvern, PA, USA

2003



FLT3 kinase
inhibitor discovery

2010



Joined the European
consortium for tumour
angiogenesis research

2012



CDK8 inhibitor
development

2019



Integration of
oncology drug
discovery suite

2019



Discovery platform for
epitranscriptomic-directed
compounds

2015



Partnership for
MedChem integration

2014



Part of the consortium
for epigenetic inhibitor
discovery

2020



Integrated discovery of
an AML drug and access
cardiac safety suite

2021



Partnership for MedChem
integration and access to
bioinformatics

2022



Partnership for R&D
of new drug
candidates

2022



Partnership for customized
peptides and antibodies
and bioanalytical assays

The Reaction Oncology Platform is your way to the successful discovery of a new cancer drug. Here is why:

Getting it right from the start

Leverage the expertise of our scientists at every level starting with the detailed and critical planning of your drug discovery endeavor.

Efficient

One scientific project manager will advance your project through the various discovery phases custom-tailored to your needs.

Easy

One MSA: A single contract with Reaction Biology covering our network of experts to reduce paperwork and complexity.

Holistic

The best team of outstanding biologists, chemists, biophysicists, and pharmacologists will provide the best chances for creating potent candidates with favorable pharmacologic profile.

The right size

As a medium-sized CRO, we are large enough to provide comprehensive end-to-end solutions, and small enough to value projects of any size.

Target Research >

Hit Identification >

Hit-to-Lead >

Lead Optimization >

Preclinical
Candidate

Target Validation

Protein Production

Assay Development

Primary Screening

Compound Screening Cascade

Medicinal Chemistry Integration

Biophysical Analysis

Mode of Action Analysis

ADME-Tox

Cardiac Safety Assessment

Cell-based Oncology

In Vivo Oncology

Biomarker Identification and Screening

Company Facts



150+

Employees



1,800

Clients worldwide



5,000

Research projects
annually



1,500

Publication citations




200

Patent citations

Our Promise: A drug candidate that is more than potent.

We take your idea from target ID through hit identification, hit-to-lead, and lead optimization to create new preclinical candidates. In addition to potency, our scientists focus on mechanistic studies to support the medicinal chemistry team.

ADME-tox and cardiac liability testing is integrated into the discovery process to ensure bioavailability and safety of new drug candidates, paving the way to successful regulatory approval.



The Reaction Biology Facilities

Reaction Biology Corporation

Locations: Malvern, PA, USA
Hersey, PA, USA
Heidelberg, Germany
Freiburg, Germany

Research capabilities: Assay development, biochemical and biophysical screening, cell-based oncology assays, in vivo pharmacology, bioassays, peptides, protein production

The expert knowledge by our globally recognized partners is key for expertly conducted drug discovery.

Symeres

- Medicinal Chemistry
- Computational Chemistry
- Synthetic Chemistry
- cGMP Production

www.symeres.com

~ 500 employees

Admescope

a Symeres company

- In vitro ADME
- In vivo DMPK
- In vitro Toxicology

www.admescope.com

Pharmacore Labs

- Cardiac safety assessment
- Ion Channel Drug Discovery

www.pharmacorelab.com

~ 20 employees

Medinoah

- Medicinal Chemistry
- PROTAC Platform
- Synthetic Chemistry
- cGMP Production

www.medinoah.com

~ 200 employees

4HF Biotec

- Bioinformatics support
- Cancer Mining Database


www.4hfbiotec.com

~ 5 employees




Built on our experience of 20+ years successful small molecule discovery targeting cancer:

The Reaction Oncology Platform



* The Reaction Oncology Platform includes a network of CROs working together under one contract with well honed communication and logistics structures to ensure seamless transitions.



The Reaction Oncology Platform

In Vivo Oncology

Biomarker

Cell-based Oncology

Mode of Action Analysis

ADME & Safety

Learn more about The Reaction Oncology Platform at www.reactionbiology.com/idd/reaction-oncology-platform

Contact us about your next drug discovery project.

Our business development executives specializing in integrated drug discovery looks forward to a conversation with you.



✉ requests@reactionbiology.com

☎ +1-610-722-0247 • +49-761-769996-0

🌐 www.reactionbiology.com

USA • Germany

Let's Discover Together.